Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? (Q37989006)

26 August 2017

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? (English)

1 reference

26 August 2017

1 reference

lymphoblastic leukemia

1 reference

Dario Campana

1

1 reference

26 August 2017

1 June 2012

1 reference

Current hematologic malignancy reports

26 August 2017

1 reference

26 August 2017

7

1 reference

26 August 2017

2

1 reference

26 August 2017

170-177

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-012-0115-4

26 August 2017

0 references

cites work

Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

New markers for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Comm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0115-4

Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris)

21 January 2018

1 reference

12 December 2020

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia

1 reference

12 December 2020

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

12 December 2020

Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL

1 reference

12 December 2020

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

1 reference

12 December 2020

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

12 December 2020

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

12 December 2020

Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences

1 reference

12 December 2020

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

1 reference

12 December 2020

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

12 December 2020

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

1 reference

12 December 2020

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

12 December 2020

The immunologic detection of minimal residual disease in acute leukemia.

1 reference

12 December 2020

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

1 reference

12 December 2020

Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia

1 reference

12 December 2020

Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukaemia

1 reference

12 December 2020

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

12 December 2020

bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

In vitro amplification of T cell gamma gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias

1 reference

12 December 2020

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

12 December 2020

Minimal residual disease in acute lymphoblastic leukemia

1 reference

12 December 2020

10.1007/S11899-012-0115-4

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22373809